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Abstract
Chemoprevention presents a major strategy for the medical management of colorectal cancer. Most drugs used for
colorectal cancer therapy induce DNA-alkylation damage, which is primarily repaired by the base excision repair (BER)
pathway. Thus, blockade of BER pathway is an attractive option to inhibit the spread of colorectal cancer. Using an in silico
approach, we performed a structure-based screen by docking small-molecules onto DNA polymerase b (Pol-b) and
identified a potent anti-Pol-b compound, NSC-124854. Our goal was to examine whether NSC-124854 could enhance the
therapeutic efficacy of DNA-alkylating agent, Temozolomide (TMZ), by blocking BER. First, we determined the specificity of
NSC-124854 for Pol-b by examining in vitro activities of APE1, Fen1, DNA ligase I, and Pol-b-directed single nucleotide (SN)-
and long-patch (LP)-BER. Second, we investigated the effect of NSC-124854 on the efficacy of TMZ to inhibit the growth of
mismatch repair (MMR)-deficient and MMR-proficient colon cancer cell lines using in vitro clonogenic assays. Third, we
explored the effect of NSC-124854 on TMZ-induced in vivo tumor growth inhibition of MMR-deficient and MMR-proficient
colonic xenografts implanted in female homozygous SCID mice. Our data showed that NSC-124854 has high specificity to
Pol-b and blocked Pol-b-directed SN- and LP-BER activities in in vitro reconstituted system. Furthermore, NSC-124854
effectively induced the sensitivity of TMZ to MMR-deficient and MMR-proficient colon cancer cells both in vitro cell culture
and in vivo xenograft models. Our findings suggest a potential novel strategy for the development of highly specific
structure-based inhibitor for the prevention of colonic tumor progression.
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Introduction
Colorectal cancer is the third most common cancer and the
second most common cause of cancer related deaths worldwide
[1]. In the year 2010, an estimated 102,900 new colorectal cases
will be diagnosed and 51,370 deaths will occur in the United States
only. Although in the last two decades an appreciable advance-
ment has been made in the treatment options, the rate of mortality
from this disease is not much improved. Therefore, new therapies
are needed to improve the prognosis of this disease. For many
years, the first choice of chemotherapeutic drug for colorectal
cancer has been 5-Fluorouracil (5-FU). It is mostly used as
neoadjuvant therapy with radiation and in combination with
several other chemotherapeutic drugs, such as mitomycin,
cisplatin, oxaliplatin, camptosar, eloxatin, avastin, erbitux, and
vectibix for the treatment of colorectal cancer that becomes
metastasized [2]. These drugs give best results at higher doses, but
cause serious side effects, including the killing of healthy cells of
lining of mouth, the lining of the gastrointestinal tract, the hair
follicles, the bone marrow and cause liver injury and hypertension
[3].
Mutations in the adenomatous polyposis coli (APC) gene is an early
event in familial adenomatous polyposis (FAP), a syndrome in
which there is an inherited predisposition to colon cancer [4,5].
Most mutations of the APC gene occur in the mutation cluster
region (MCR) and result in the production of a truncated protein.
This truncation compromises several functions of APC, which is
involved in chromosomal instability and abnormal functioning of
Wnt-signaling pathway, cell cycle regulation, stabilization of the
microtubular cytoskeleton, cell-cell interactions and DNA rep y
[6–14]. Recent studies suggest that the nuclear APC, through a
region (amino acids 1441-2077) that is truncated in the majority of
colorectal tumors, cooperates in the recruitment of DNAPKcs to
the damaged DNA chromatin and enhances early response to
double-strand breaks (DSB) DNA repair [15]. APC also interacts
directly with genomic DNA, preferentially with A/T rich
sequences [16], implying a role for APC in DNA replication
[17]. It has been suggested that APC through its C-terminus end
(amino acids 2140-2421) interacts with DNA and negatively
regulates cell cycle progression through inhibition of DNA
replication by direct interaction with DNA [17]. We have
previously shown that treatment with DNA-alkylating agents
enhances the level of APC in colorectal cancer cells [14]. In
addition, we demonstrated that APC interacts with DNA
polymerase b (Pol-b) and flap-endonuclease 1 (Fen1) and blocks
Pol-b-directed single-nucleotide (SN)- and long-patch (LP)-base
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chemotherapy [14,18]. Based upon these studies, it appears that
the interaction of APC with Pol-b and other BER proteins can be
an appropriate target for chemotherapeutic intervention of
colorectal cancer growth.
The use of DNA-alkylating agents as chemotherapeutic drugs is
based on their ability to trigger a cell death response [19], and
their therapeutic efficacy is determined by the balance between
DNA damage and repair. The DNA-alkylation damage-induced
lesions are repaired by the BER, O
6-methylguanine DNA-
methyltransferase (MGMT) and mismatch repair (MMR) path-
ways. Many colon tumors become resistant to DNA-alkylating
agents due to overexpression of MGMT or MMR-deficiency [20].
The cells deficient in MGMT are unable to process the O
6MeG
during DNA synthesis, and if it is not repaired, a G:C to G:T
transition mutation occurs [21]. In previous studies, the role of
BER pathway has also been implicated in cellular resistance to
TMZ [22,23], which depends on specific BER gene expression
and activity [24]. In the past years, the anticancer drugs that have
been developed mainly target the MGMT and MMR pathways
[25,26]. Since MMR-deficient colorectal cancers pose a greater
risk of resistance to DNA-alkylating drugs due to overexpression of
MGMT or MMR-deficiency [27–29], it is critical to discover a
chemotherapeutic strategy that can be useful for the treatment of
both MMR-deficient and MMR-proficient colorectal tumors.
Interestingly, although BER is responsible for the repair of 70%,
5% and 9% of N
7-methylguanine (MeG), N
3-MeG, and N
3-
methyladenine (MeA) lesions, respectively, induced by the DNA-
alkylating drug Temozolomide (TMZ; NSC-362856) [23,30,31],
the potential utility of BER pathway blockade has not been
thoroughly explored. Thus, with the combination of BER blocking
agents and TMZ treatment, the clinical outcome of chemother-
apeutic efficacy of TMZ can be enhanced. Previous studies also
support that DNA alkylation-induced damage is primarily
repaired by the BER pathway [26,27]. In the past, BER pathway
has been utilized as a target for the development of new drugs, but
the clinical implication of these drugs is still under investigation
[31–36].
TMZ has been successfully being used for the treatment of
metastatic melanoma and glioblastoma multiforme, the latter in
combination with radiotherapy [37,38], but has been shown to be
less effective in the treatment of other malignancies. A Phase II
clinical study of TMZ in pre-selected advanced aerodigestive tract
cancers, including colorectal neoplasm, has been recently
completed by Schering-Plough, Kenilworth, NJ, showing only a
partial response to the treatment (http://clinicaltrials.gov/ct2/
show/NCT00423150). In an earlier Phase I clinical study of
TMZ, a partial response of the drug on metastatic colorectal
cancer was also observed, suggesting considerable tumor resistance
to treatment [39]. To overcome the resistance of TMZ, a Phase II
clinical study was performed in which lomeguatrib was combined
with TMZ, but the results were not very significant [40]. Thus,
there is an urgent need of the development of a new strategy by
which the efficacy of TMZ can be increased for the treatment of
colorectal cancers.
Since most chemotherapeutic drugs cause DNA damage and
resistance due to activation of the DNA repair pathway(s),
targeting proteins of these pathway(s) to block their activity can
be a promising strategy for the development of novel drugs with
higher efficacy to both chemo-resistant and sensitive tumors. In
recent years, structure-based virtual design and the three-
dimensional structure of a drug-target interaction with small
molecular weight inhibitors has been used to guide rationale drug
discovery [41]. The computer-aided drug design could find new
lead compounds and aided in the structure optimization for
biological and pharmacological tests [42–44]. In the present study,
we performed structure-based molecular docking of Pol-b at the
site where adenomatous polyposis coli (APC) interacts and blocks
Pol-b-directed BER [14,45,46]. The structure-based molecular
docking is considered a suitable approach for the development of
new drugs, since this approach is targeted to specific protein and
specific pathway [47]. Based upon in silico efforts, we have
identified a highly potent small molecular weight inhibitor, NSC-
124854 {[5-(4-amino-6-iodo-2-oxo-5,6-dihydropyrimidin-1-yl)-3-
hydroxy-oxolan-2-yl] methoxyphosphonic acid}, which specifical-
ly interacts with Pol-b and blocks Pol-b-directed single-nucleotide
(SN)- and long-patch (LP)-BER. Here we present data describing
that NSC-124854 can enhance the efficacy of TMZ in MMR-
deficient and proficient colon cancer cells in vitro and in vivo models.
We propose that these pre-clinical findings will establish a new
paradigm for clinical management of colon cancer.
Results
Screening of small molecules to inhibit Pol-b-directed
strand-displacement activity
To identify a potent anti-Pol-b compound, we used an in silico
high-throughput structure-based molecular docking approach and
screened approximately 140,000 small molecule compounds
(molecular weight ,500 daltons) for their ability to interact with
the APC-binding site of Pol-b (Fig. 1A) [48]. The 22 highest
scoring small molecular compounds were requested from the
Developmental Therapeutics Program (DTP) of National Cancer
Institute (NCI) for functional evaluation. We performed the initial
screening of the compounds for determining their ability to inhibit
Pol-b-directed strand-displacement synthesis. We used an in vitro
reconsitiuted assay system in these studies. We screened 22 top
scoring compounds and the data of 12 compounds is shown here
(Fig. 2A–C). Among 22 small molecules, NSC-21371 and NSC-
91855 inhibited Pol-b-directed strand-displacement synthesis at
125 mM concentration (Fig. 2B; compare lane 3 with lanes 9–13
and 19–23, respectively). These small molecular compounds did
not affect 1-nt incorporation activity (24-mer product) of Pol-b at
any tested concentration. However, NSC-124854 inhibited Pol-b-
directed strand-displacement activity at 5 mM concentration, while
higher concentrations of NSC-124854 completely abrogated the
formation of strand-displacement products (Fig. 2A; comparison of
lane 3 with lanes 4–8 respectively). When the concentration of
NSC-124854 was further increased to 50 mM or more, the 1-nt
incorporation (24-mer product) activity of Pol-b was completely
blocked as shown by the accumulation of 23-mer incision product
and lack of 1-nt incorporation product, reflecting a complete loss
of Pol-b activity (Fig. 2A, compare lane 3 with 4–8, respectively).
These results suggest that NSC-124854 is a most potent inhibitor
of Pol-b activity among all the compounds tested.
Small molecule inhibitor, NSC-124854, specifically blocks
Pol-b activity
We further determined whether NSC-124854 is a specific
inhibitor of Pol-b activity or it might also block the activity of other
BER enzymes. We first determined the IC50 of NSC-124854 for
Pol-b-directed strand-displacement synthesis. This experiment was
the same as described in the screening experiment, except we
chose lower concentrations to determine the IC50 of NSC-124854.
We quantitated the strand-displacement synthesis products
(Fig. 3A, lanes 3-10, respectively) and plotted as a percent of
change of NSC-124854-mediated blockage of Pol-b activity
(Fig. 3B). The treatment with NSC-124854 showed a dose-
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with an IC50 of 5.3 mM (Fig. 3B). These results suggest that NSC-
124854 has a strong inhibitory effect on Pol-b-directed strand-
displacement synthesis.
Next, we determined whether NSC-124854 can inhibit the
activity of other BER pathway enzymes such as apurinic/
apymidinic endonuclease 1 (APE1), Fen1 and DNA ligase I.
Results showed that NSC-124854 did not inihibit the activities of
these enzymes (Fig. 4A–C, respectively). From these results, we
concluded that the inhibitory effect of NSC-124854 was highly
specific for Pol-b and did not affect the activity of other BER
enzymes.
Small molecule inhibitor NSC-124854 blocks
single-nucleotide (SN)- and long-patch (LP)-BER
activities in a reconstituted in vitro assay
Based upon molecular docking analysis, NSC-124854 is
predicted to form polar (H-bonds) interactions with the amino
acid residues Lys81 and Arg89 and a non-polar (van der Waals)
interaction with the amino acid residue Asp17 on the surface of
Pol-b [48,49]. These residues are in close proximity of the APC
binding pocket (amino acid residues Thr79, Lys81 and Arg83)
(Fig. 1B). These predicted contacts suggest a multiple direct
contacts between NSC-124854 and Pol-b, which can possibly
mimic the interaction of APC with Pol-b. Since these data suggest
that NSC-124854 in combination with TMZ as a possible
chemotherapeutic treatment strategy for colorectal cancer, we
undertook a study to determine the efficacy and limitations of this
strategy.
Although we determined the specificity of NSC-124854 for Pol-
b activity as shown in Fig. 3 and 4, it was necessary to examine the
effect of this compound when the complete BER system of SN-
and LP-BER is assembled. These experiments will provide
biochemical evidence for the potency of NSC-124854. We used
63-mer
32P-labeled U-DNA as a substrate (Fig. 5A) for SN-BER.
Since Fen1 is required for LP-BER activity and can stimulate Pol-
b activity for strand-displacement synthesis [50,51], we adopted
same strategy for determining the effect of NSC-124854 on LP-
BER (Fig. 5B). After APE1 incision, an expected 23-mer product
was generated (Fig. 5C; compare lane 1 with 2). The results
showed efficient 1-nt incorporation (24-mer product) by Pol-b
which was ligated with DNA ligase I to generate 63-mer repaired
product (Fig. 5C, lane 5). The addition of Fen1 stimulated Pol-b
activity for strand-displacement synthesis (Fig. 5C, lane 4), which
was also ligated with DNA ligase I to generate 63-mer repaired
product (Fig. 5C, lane 6). The addition of NSC-124854 blocked
Pol-b-directed 1-nt addition (24-mer product in the absence of
Fen1) (Fig. 5C, compare lane 3 with 7) as well as strand-
displacement synthesis in the presence of Fen1 in a dose-
dependent manner (Fig. 5C, compare lane 4 with lanes 8–11,
respectively). Further, the complete repair by SN- and LP-BER
sub-pathways after the addition of DNA ligase I was also blocked
by NSC-124854 in a dose-dependent manner (Fig. 5C, compare
lanes 12–15 and 16–19, respectively).
Expression of wild-type APC causes resistance to TMZ
treatment which is abolished by the treatment with
NSC-124854
In previous studies, we have shown that APC interacts with Pol-
b and Fen1 and blocks SN- and LP-BER activities [14,45,46,52–
54]. We have also shown that HCT-116 cells (express wild-type
APC) are more sensitive to methylmethane sulfonate (MMS) and
TMZ treatments than HCT-116-APC(KD) cells (knocked-down
APC with pSiRNA) [36,45,46]. In the present study, we
determined the sensitivity of TMZ in the presence of NSC-
124854 to several colon cancer cell lines (HCT-116, HCT-116-
APC(KD), HCT-116+ch3, Caco-2, HT29, SW480, LoVo and
RKO) using a clonogenic assay [18,36,46]. The IC50 results
showed that all the cell lines tested showed higher sensitivity to the
combination treatment of NSC-124854 with TMZ (Table 1). The
IC50 data showed that NSC-124854 was able to enhance the
growth inhibitory effect of TMZ to both HCT-116 and HCT-116-
Figure 1. NSC-124854 complex with the simulated structure of Pol-b. Panel A shows the predicted interaction of NSC-124854 based on the
crystal structure of Pol-b. Pol-b is shown in gold and side-chains predicted to form contacts with NSC-124854, Asp17 and Arg89, are depicted with
gold for carbon, blue for nitrogen and red for oxygen. The APC binding pocket residues, Thr79, Lys81, Arg83 of Pol-b are shown as spheres colored
gray for carbon, blue for nitrogen and red for oxygen. Polar contacts are depicted as yellow dashed lines between NSC-124854 and Pol-b residues
Lys81 and Arg89. The figure was made with PyMol. Panel B depicts Pol-b-ligand interactions predicted based on the posed molecular docking
orientation of NSC-124854. Interactions mediated by hydrogen bonds (green) and by hydrophobic (gray) contacts are shown. NSC-124854 and Pol-b
are shown in black for carbon, blue for nitrogen and red for oxygen. Inter-atomic bonds of NSC-124854 are shown in magenta. Inter-atomic bonds of
Pol-b are shown in gold. Hydrogen bonds are indicated by dashed lines between the atoms involved, while hydrophobic contacts are represented by
an arc with spokes radiating towards the NSC-124854 atoms they contact. The contacted Pol-b atoms are shown with spokes radiating back. The
figure was made with HBPLUS and LigPlot.
doi:10.1371/journal.pone.0016691.g001
Structure-Based Therapy for Colorectal Cancer
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e16691APC(KD) cell lines; however, the effect was greater in HCT-116
than in HCT-116-APC(KD) cells (Table 1). These results confirm
our previous findings that wild-type APC by inhibiting BER
pathway increases the sensitivity of DNA-alkylaying drugs
[36,46,54]. However, other cell lines which express either wild-
type or truncated APC, such as RKO (310 kDa), SW480
(147 kDa), Caco-2 (150 kDa), LoVo (120 kDa) and HT29 (110
and 200 kDa) did not show a direct correlation of the role of APC
in the sensitivity of these drugs. These results suggest that genetic
factors other than mutations in the APC gene might also play a role
in determining the sensitivity of NSC-124854 and TMZ to
different colon cancer cells. One of the critical parameters for this
differential sensitivity is controlled by the differential status of
MMR activity, which is discussed below.
Combination treatment of NSC-124854 enhances
growth inhibitory effect of TMZ on MMR-deficient and
MMR-proficient colon cancer cells
MMR proteins are involved in the chemotherapeutic response
of colon cancer cells, and defect in MMR protein(s) is present in
the hereditary nonpolyposis colorectal cancer (HNPCC) [55]. Two
Figure 2. Screening of small molecules. To determine the effect of compounds on the blockage of Pol-b-activity, we assembled in vitro strand-
displacement synthesis assay with purified APE1 precut
32P-labeled 63-mer F-DNA and Pol-b. Panel A (NSC-124854, NSC-143995, NSC-160172 and
NSC-263659), B (NSC-10730, NSC-21371, NSC-43656 and NSC-91855) and C (NSC-274937, NSC-351093, NSC-668472 and NSC-674711) show the effect
of small molecules on Pol-b-directed strand displacement synthesis. In each Panel, lane 1 shows 63-mer
32P-labeled F-DNA, lane 2 shows 23-mer
product after APE1 incision, lane 3 shows 1-nt incorporation (24-mer) and strand-displacement products. Lanes 4–8, 9–13, 14–18 and 19–23 show the
strand-displacement activity of Pol-b incubated with 0, 5, 10, 25, 50 and 125 mM, respectively, of the indicated compounds. Data are representative of
two experiments.
doi:10.1371/journal.pone.0016691.g002
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cancers, MLH1 and MSH2. MMR-deficient cells are frequently
resistant to DNA-alkylating agents [55]. To determine the role of
MMR in the combination effect of NSC-124854 with TMZ on the
growth inhibition, we used several MMR-proficient and MMR-
deficient colon cancer cell lines. HCT-116, HCT-116-APC(KD),
and RKO cell lines are deficient in MMR due to lack of expression
of hMLH1, a key enzyme of this pathway [56], while LoVo cells
are MMR-deficient due to absence of MSH2 expression [57]. The
HCT-116+ch3 cell has been made MMR-proficient by introduc-
ing a single copy of chromosome 3 harboring the hMLH1 gene
[58]. TMZ is known to cause resistance to MMR-deficient cells
[26]. In previous studies, it has been suggested that the disruption
of BER pathway can abolish drug resistance caused by MMR-
deficiency [59]. In the present study, we determined whether
treatment of TMZ sensitizes MMR-proficient cells comparatively
more than the MMR-deficient cells, and whether the blockade
of BER pathway by NSC-124854 can abolish TMZ resistance
to MMR-deficient cells. As expected, the MMR-proficient cell
lines SW480 (IC50 108.163.2 mM), HCT-116+ch3 (IC50
130.764.3 mM) and Caco-2 (IC50 449.2642.4 mM), except
HT29 (IC50 962.7662.7 mM) showed a higher sensitivity to
TMZ as compared to MMR-deficient cell lines HCT-116 (IC50
739.0625.9 mM), HCT-116-APC(KD), (IC50 877.7649.2 mM),
LoVo (IC50 838.8653.1 mM) and RKO (IC50 1572.6689.9 mM)
(Table 1). Furthermore, the combination treatment of NSC-
124854 further reduced the IC50 of TMZ by two-fold in all the
seven cell lines regardless of their status of MMR activity (Table 1).
These results suggest that the combination treatment of NSC-
124854 with TMZ could be a useful chemotherapeutic strategy for
the management of both MMR-deficient and MMR-proficient
colorectal tumors.
Combination of NSC-124854 with TMZ can be used as a
potential chemotherapeutic approach to augment
colonic tumor growth in vivo
To further verify the in vitro results of the efficacy of the
combination treatment of NSC-124854 and TMZ with a well-
characterized and specific target of Pol-b to reduce the doses of
TMZ that can eliminate side-effects and simultaneously abolish
the MMR-resistance, we performed an in vivo xenograft study
using severe combined immunodeficient (SCID, lacking functional
T and B cells) mouse, as described in Figure 6A. Our choice for
female mice was based on recent study describing that the
estimated new cases of colon cancer in 2009 was predicted to be
higher in females compared to males [60]. We chose a dose of
20 mg/kg body weight of TMZ for these experiments, which is
10- and 4-times lower than the maximum tolerated dose in mice
and human, respectively [61–65]. Also, the dose of 10 mg/kg
body weight for NSC-124854 is more than 20-times lower than its
IC50 in culture (Table 1). Although we have not determined the
maximum tolerated dose (MTD) of NSC-124854 in mice, the
chosen concentration is very much in the safer range.
These drugs were given intraperitoneally (i.p.) for five
consecutive days. The growth inhibition of tumors was monitored
up to 42 days. The results showed an increase in the tumor volume
in the control group in a time-dependent manner for all the cell
lines, i.e., HCT-116, HCT-116-APC(KD) and HCT-116+ch3.
The tumor volume reached a maximum of 1,120 mm
3 within 42
days of xenograft implantation, which is shown in Figure 6B. The
tumor growth in the untreated HCT-116 xenograft was higher
than HCT-116-APC(KD) and HCT-116+ch3 cells. The anti-
tumor effect of TMZ alone was significantly different in HCT-
116+ch3 cells (MMR-proficient) and was less pronounced in
HCT-116 and HCT-116-APC(KD) cells (Fig. 6B). Treatment with
NSC-124854 alone also decreased the growth of tumors with all
the cell lines, which was more pronounced when it was combined
with TMZ (Fig. 6B). These results suggest that the combination
treatment of NSC-124854 enhances the therapeutic efficacy of
TMZ equally well in both MMR-deficient and MMR-proficient
xenograft tumor model in vivo. To determine the tolerance of the
drugs, we recorded the body weight of the animals twice a week
until the end of the experiment. The results showed a similar gain
in body weight of control and treated group of animals with NSC-
124854 and TMZ alone or in combination (data not shown).
Thus, it appears that the doses of 10 mg/kg body weight for NSC-
Figure 3. NSC-124854 blocks Pol-b-directed strand-displacement synthesis with a very low IC50. To determine the affinity of NSC-124854
for the blockage of Pol-b-directed strand-displacement activity, we determined its IC50 in a reconstituted assay system as in described in Figure 2.
Panel A shows the autoradiogram of the strand-displacement activity. Lane 1 shows
32P-labeled 63-mer F-DNA, lane 2 shows 23-mer product after
APE1 incision, and lane 3 shows strand-displacement activity of Pol-b. Lanes 4–10 shows effect of 0.5–20 mM of NSC-124854 on Pol-b activity. Panel B
shows the IC50 data. NSC-124854 inhibited Pol-b-directed strand-displacement activity in a dose dependent manner with an IC50 of 5.3 mM. Data are
the representative of two independent estimations.
doi:10.1371/journal.pone.0016691.g003
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and did not cause any obvious adverse side effects in our
experimental animals.
Discussion
In previous studies, Pol-b has been used as a target for
chemotherapeutic drug development [23,34], but did not reach
beyond the pre-clinical level. The efficacy of the previous
compounds has been less effective because they require very high
concentrations to achieve the desired cytotoxicity in vitro and they
were not tested systematically in vivo. Furthermore, they were
mainly targeted to block SN-BER. The use of TMZ for the
treatment of malignancies other than glioblastoma and melanoma
has been limited, especially for the treatment of colorectal tumors,
due to less pronounced effect on suppression of tumor growth
[39,40]. In the present study, we used structure-based molecular
approach to identify small molecule which can mimic the
interaction of APC with Pol-b and block Pol-b-directed BER that
can be utilized as a chemotherapeutic target. Our strategy of
molecular docking in the APC-binding pocket of Pol-b was to
identify a small molecule which can block both SN- and LP-BER
activities and demonstrate cytotoxicity in both in vitro and in vivo
assays at lower concentrations.
Notably, if successful, the proposed strategy will be highly
effective in the prevention of both MMR-proficient and MMR-
deficient colorectal cancers; this is of importance because the
MMR-deficient colorectal cancers pose a greater risk of resistance
to DNA-alkylating drugs due to over-expression of MGMT or
MMR-deficiency [27–29]. The cells deficient in MGMT are
unable to process the O
6MeG during DNA synthesis, and if
unrepaired, a G:C to G:T transition mutation occurs [27]. The
G:T mismatch is then repaired by MMR pathway [28]. However,
if the O
6MeG is not repaired before the re-synthesis step in MMR,
the thymine is likely to be re-inserted opposite to the lesion. It is
believed that the repetitive cycle of futile MMR results into a
generation of tertiary lesions, most likely gapped DNA. This then
gives rise to double-stranded breaks (DSBs) in DNA that elicits a
cell death response [29,66]. Furthermore, it has been shown that
TMZ causes resistance to MMR-deficient colonic tumors and
limits its use in the treatment of these cancers [67]. Thus, a
chemotherapeutic strategy that can induce cell death in both
MMR-proficient and MMR-deficient colon cancer cells is highly
desirable [68]. Our results indicate that the strategy of combining
NSC-124854 with TMZ seems to be effectively blocking the
growth of both MMR-proficient and MMR-deficient colon cancer
cells in vitro and causing anti-tumor activity in vivo, which supports
the previous findings [27,59]. This suggests that the blockade of
the repair of TMZ-induced N
7-MeG, N
3-MeG, N
3-MeA lesions
(non-mutagenic) by NSC-124854 causes much higher cytotoxicity
than the mutagenic lesions of O
6-MeG. Thus, our approach of
combining NSC-124854 with TMZ shows promise in that NSC-
124854 can overcome TMZ-induced resistance at lower doses and
increase its efficacy against colorectal cancer. Since our strategy is
to block Pol-b activity by small molecular compounds and increase
the efficacy of TMZ, it will also benefit patients who carry wild-
type or mutant APC gene; the mutant APC gene is the precursors
of adenomas and carcinomas in familial adenomatous polyosis
(FAP) colon cancer.
Based on our in vitro and in vivo results there are certain points
which need further discussion regarding the tumor growth
inhibition after drug treatments. In the in vitro studies, we clearly
demonstrated that APC caused sensitization of HCT-116 cells
than HCT-116-APC(KD) cells. Also, the MMR-proficient HCT-
116+ch3 cells were more sensitive to TMZ treatment than MMR-
deficient HCT-116 and HCT-116-APC(KD) cells. These in vitro
results did not translate in a similar fashion to in vivo results in
which the effect of TMZ on MMR-proficient and MMR-deficient
xenografts was not as prominent as was seen with in vitro assays. It
appears that the dose of TMZ (20 mg/kg body weight) used for in
vivo studies, perhaps, was high enough to show the difference in the
sensitivity of MMR-proficient and MMR-deficient cells. A similar
observation has been made in previous studies as well where even
up to two-fold higher concentration of TMZ (40 mg/kg body
Figure 4. NSC-124854 does not block the activity of APE1, Fen1
and DNA ligase I in reconstituted in vitro assays. Panel A shows
the effect of NSC-124854 on APE1 activity. APE1 (10 nM) was incubated
with different concentrations of NSC-124854 (0.5-20 mM, lanes 3-9,
respectively) and
32P-labeled 63-mer F-DNA. Lanes 1 and 2 show uncut
32P-labeled 63-mer F-DNA and 23-mer incision product, respectively.
Panel B shows the effect of NSC-124854 on Fen1 activity. Fen1 (10 nM)
was incubated with different concentrations of NSC-124854 (0.5–20 mM,
lanes 3–9, respectively) and
32P-labeled 51-mer flapped-DNA. Lane 1
shows the position of 51-mer labeled oligonucleotide and lane 2 shows
11-mer cleaved flap product. Panel C shows the effect of NSC-124854
on DNA ligase I activity. DNA ligase I (5 nM) was incubated with
different concentrations of NSC-124854 (0.5–20 mM, lanes 3–9, respec-
tively) followed by addition of 2.5 nM of
32P-labeled 63-mer nicked
DNA. Lane 1 shows 23-mer labeled oligonucleotide (nicked product)
and lane 2 shows 63-mer ligated product. Data are representative of
two independent experiments.
doi:10.1371/journal.pone.0016691.g004
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growth inhibition of MMR-proficient and MMR-deficient colon
cancer cells [33]. Another point which we noted in these studies
was the effect of NSC-124854 alone on the decrease of growth of
xenograft tumors, although it was significant only with HCT-
116+ch3 tumors. We initially predicted that NSC-124854 being
specific for Pol-b will show no effect on tumor growth if treated
alone. However, the effect of NSC-124854 alone on the growth of
xenograft tumors observed in this study could be due to the
production of more abasic lesions than cells in culture, which
sensitizes these xenograft tumor cells to the treatment with NSC-
124854. Also, it is possible that NSC-124854 blocks critical cell
survival pathways which are active in xenograft tumors but not in
cultured cells. The doses of NSC-124854 (10 mg/kg body weight)
and TMZ (20 mg/kg body weight) which we used in these studies,
seems to be well tolerated by the animals. However, it will be
necessary in the future to determine the maximum tolerated dose
(MTD) of NSC-124854 alone and together with TMZ so that a
highest efficacy of these drugs can be translated into clinical
practice. Importantly, although these studies are focused on a lead
small molecular compound, NSC-124854, it provides insight into
the rational development of second generation small molecular
compounds with greater potency and specificity for the treatment
of colon cancer. The results allow us to discuss the ‘‘proof-of-
principle’’ by which Pol-b-targeted compounds enhance the
efficacy of TMZ. Thus, by developing a target-defined strategy
of chemotherapy and with the appropriate understanding of the
mechanism of action, the strategy of combination of NSC-124854
with TMZ may provide a foundation for both clinical and
scientific development of colon cancer management.
Materials and Methods
Cell lines
Human colon cancer cell lines HCT-116, SW480, RKO, Caco-
2, LoVo and HT29 were obtained from ATCC (Manassas, VA).
HCT-116-APC(KD) cell line was established in our laboratory
[52], and HCT-116+ch3 cell line was a gift from Dr. Tom Kunkel
(NIEHS, Research Triangle Park, NC) [69]. HCT-116, HCT-
116-APC(KD) and HCT-1116+ch3 cells were grown in McCoy’
5a, RKO and Caco-2 cells were grown in MEM, and LoVo cells
were grown in Ham’s F-12 medium at 37uC under a humidified
atmosphere of 5% CO2. For each cell line, the medium was
supplemented with 10% fetal bovine serum (Hyclone, Logan, UT)
100 U/ml of penicillin, and 100 mg/ml of streptomycin.
Oligonucleotides and Chemicals. All oligonucleotides were
purchased from Sigma-Genosys (Woodlands, TX). Restriction
enzymes and T4-polynucleotide kinase (PNK) was purchased from
New England Biolabs (Ipswich, MA) and radionuclide [c-
32P]ATP
was purchased from Perkin Elmer, Inc. (Boston, MA).
Molecular docking
The molecular docking was performed using the atomic
coordinates extracted from the crystal structure of human Pol-b
Figure 5. NSC-124854 blocks Pol-b-directed SN- and LP-BER activities. Panels A and B represent the protocols of the SN- and LP-BER,
respectively. Panel C shows the autoradiogram describing the effect of varying concentrations of NSC-124854 on SN- and LP-BER activities. Lane 1
shows 63-mer
32P-labeled U-DNA, Lane 2 shows 23-mer product after APE1 incision, Lane 3 shows 1-nt incorporation by Pol-b, Lane 4 shows strand-
displacement products after the addition of Fen1. Lanes 5 and 6 show the 63-mer ligated product of SN- and LP-BER activities, respectively. Lane 8-19
shows the effect of NSC-124854 on the blockage of 1-nt (24-mer product) incorporation. Lanes 8-11 depict NSC-124854-mediated block of strand-
displacement synthesis. Furthermore, lanes 12–15 and lanes 16–19 show the effect of NSC-124854 on the blockage of SN- and LP-BER activities in a
dose-dependent manner. Data is a representative of three different experiments.
doi:10.1371/journal.pone.0016691.g005
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Approximately 140,000 small molecules from the NCI/DTP
database were positioned in the selected structural pocket (which
includes amino acid residues T79/K81/R83 of Pol-b) and scored
based on predicted polar (H-bond) and non-polar (van der Waals)
interactions. Each of the small molecules was positioned in the
selected site in 100 different orientations. The best orientation and
scores (contact and electrostatic) were calculated. The grid based
scoring algorithm approximates van der Waals and H bond
interactions. Ten mg of the 22 highest-scoring compounds for the
selected structural pocket were obtained for use in Pol-b inhibition
assays from the NCI/DTP.
Screening of small molecules to examine blockade of Pol-
b-directed displacement activity. To identify a potent anti-
Pol-b compound, we screened top 22 scoring small molecular
compounds for determining their ability to block Pol-b activity for
functional evaluation. We used in vitro Pol-b-directed strand-
displacement activity assay for the initial screening of the
compounds. Briefly, the strand-displacement reaction mixture
was assembled in 30 ml volume with 30 mM Hepes, pH 7.5,
30 mM KCl, 8.0 mM MgCl2, 1.0 mM DTT, 100 mg/ml BSA,
0.01% (v/v) Nonidet P-40, 2.5 nM of
32P-labeled 63-mer F-DNA
substrate, 2 nM of APE, 5 nM of Pol-b and 0-125 mM of NSC-
124854. The reaction mixture was incubated for 30 min at 37uC
and terminated by the addition of 30 ml of stop solution (5.0 mM
of EDTA, 0.4% (w/v) SDS). DNA was extracted with an equal
volume of phenol/chloroform/isoamyl alcohol (25:24:1, v/v)
followed by ethanol precipitation. The strand-displacement
products were resolved on a 15% polyacrylamide-7 M urea gel.
APE1 assay. The in vitro APE1 activity was determined in the
presence and absence of different concentrations of NSC-124854.
The reaction mixture in a 30 ml volume contained 30 mM of
Table 1. Effect of NSC-124854 on TMZ-mediated cell growth
inhibition of MMR-proficient and MMR-deficient colon cancer
cell lines in culture.
IC50 of TMZ (mM)
NSC-666715
(mM) 0 25 50 100
MMR-proficient
HCT-116+ch3 130.764.3 119.763.0 88.766.4** 68.063.6***
Caco-2 449.2642.4 -- 254.166.7* --
HT29 962.7662.7 -- 407.6623.1*** --
SW480 108.163.2 -- 43.569.6** --
MMR-deficient
HCT-116 739.0625.9 644.0619.3* 468.7625.8** 344.3617.2***
HCT-116-APC(KD) 877.7649.2 744.765.3 549.762.7** 410.366.6***
LoVo 838.8653.1 -- 431.66103.0* --
RKO 1572.6689.9 -- 1068.76195.3 --
Cells were treated with different concentrations of NSC-124854 either alone or
in combination with TMZ for 48 h. The cell growth inhibition was determined
by the clonogenic assay. The IC50 of NSC-124854 for HCT-116, HCT-116-APC(KD)
and HCT-116+ch3 is 210 6 12.0, 251.763.3 and 391.4668.5, respectively. The
IC50 of NSC-124854 in Caco-2, HT29, SW480, LoVo and RKO was not
determinable up to 250 mM of NSC-124854 concentration used in these
experiments. Data presented are the mean 6 SE of three different estimations.
Statistically significant results are shown as asterisks. The p value of the
Student’s t-test as compared to TMZ treated group is: *, p,0.05; **, p,0.005;
and ***, p,0.001.
doi:10.1371/journal.pone.0016691.t001
Figure 6. NSC-124854 in combination with TMZ decreases the growth of tumors in a xenograft model. Panel A shows the schematic
representation of the experimental protocol. Panel B shows the change in tumor volume at the 42
nd day of the experiment. Data presented are the
mean 6 SD of four to six animals in each group. *, significantly different than control;
{, significantly different than NSC-124854. P,0.05.
doi:10.1371/journal.pone.0016691.g006
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DTT and 100 mg/ml of BSA. Briefly, 5 nM of APE1 was
incubated with 0-20 mM of NSC-124854 and reaction was
initiated by addition of 2.5 nM of
32P-labeled 63-mer F-DNA
substrate. Reaction was incubated for 20 min at 37uC and
terminated by the addition of 30 ml of stop solution (5.0 mM of
EDTA, 0.4% (w/v) SDS). DNA was extracted with an equal
volume of phenol/chloroform/isoamyl alcohol (25:24:1, v/v)
followed by ethanol precipitation. APE1 incised product was
resolved on a 15% polyacrylamide-7 M urea gel.
Fen1 endonuclease assay. The in vitro Fen1 activity was
determined in the presence and absence of different
concentrations of NSC-124854. The reaction mixture in a 30 ml
volume contained 30 mM of Hepes, pH 7.5; 30 mM of KCl,
8.0 mM of MgCl2, 1.0 mM of DTT and 100 mg/ml of BSA
[18,52]. Briefly, 10 nM of Fen1 was incubated with 0-20 mMo f
NSC-124854 at room temp for 5 min followed by addition
2.5 nM of
32P-labeled 51-mer flapped-DNA substrate. Reaction
was allowed to proceed for 20 min at 37uC and terminated by the
addition of 20 ml of stop solution (5.0 mM of EDTA, 0.4% (w/v)
SDS). DNA was extracted with an equal volume of phenol/
chloroform/isoamyl alcohol (25:24:1, v/v) followed by ethanol
precipitation. The 11-mer reaction products were resolved on a
15% polyacrylamide-7 M urea gel.
DNA ligase I assay. The in vitro DNA ligase I activity was
determined in the presence and absence of different
concentrations of NSC-124854. The reaction mixture in a 30 ml
volume contained 30 mM of Hepes, pH 7.5; 30 mM of KCl,
8.0 mM of MgCl2, 1.0 mM of DTT and 100 mg/ml of BSA as
described earlier [52]. Briefly, 5 nM of DNA ligase I was
incubated with 0–20 mM of NSC-124854 at room temp for
5 min followed by addition 2.5 nM of
32P-labeled nicked-DNA
substrate. Reaction was incubated for 60 min at 37uC and
terminated by the addition of 30 ml of stop solution (5.0 mM of
EDTA, 0.4% (w/v) SDS). DNA was extracted with an equal
volume of phenol/chloroform/isoamyl alcohol (25:24:1, v/v)
followed by ethanol precipitation. The reaction products were
resolved on a 15% polyacrylamide-7 M urea gel.
In vitro BER assays with purified proteins
The procedure for BER assays were essentially the same as
described in our previous studies [18,36,45,46,52]. Briefly, the
BER reaction mixture contained 30 mM Hepes, pH 7.5, 30 mM
KCl, 8.0 mM MgCl2, 1.0 mM DTT, 100 mg/ml BSA, 0.01% (v/
v) Nonidet P-40, 0.5 mM ATP, and 20 mM each of dATP, dCTP,
dGTP, dTTP in a final volume of 20 ml. The following additions
were made to the above mixture: (i) For SN-BER, 2.5 nM of
32P-
labeled 63-mer U-DNA (containing uracil at the 24
th position, pre-
incubated with 1 unit of UDG to create an abasic site and 1 nM
APE1 to create an incision at the 59 end of the repair site), 5 nM of
Pol-b and different concentrations of NSC-124854; and (ii) For
LP-BER, the reaction mixture was assembled similarly as for SN-
BER, except Fen1 was included in the reaction mixture. The
repair was initiated with the addition of 0.4 nM of DNA ligase I.
Clonogenic assays
A single cell suspension of HCT-116, HCT-116-APC(KD), and
HCT-116+ch3 cells were plated 200 cells/well, while HT29,
SW480, LoVo, Caco-2 and RKO cells were plated 400 cells/well
in triplicate in a six-well plates. Cells were pretreated for 1 h with
NSC-124854 or vehicle (0.1% DMSO) followed by treatment with
varying concentrations of TMZ for 48 h. After the treatment, the
culture medium was replaced with fresh medium and cells were
allowed to grow for an additional 8 days. Visible colonies of more
than 50 cells were stained with methylene blue and counted for
viability [18,36,46].
Xenograft studies
Female homozygous, 6-week old, SCID mice purchased from
Taconic Farms, Inc., were used in the study. Prior to initiate the
animal experiment, the animal protocol was submitted to the
Animal Investigation Committee (AIC) of Wayne State University.
This is the Institutional Review Board called AIC Committee who
approves animal protocols. All other animal-related research
approvals including ethics are also obtained through this
committee. The protocol was approved in March 6, 2008 with
the protocol number A04-06-08, which will expire on April 30,
2011. HCT-116, HCT-116-APC(KD) and HCT-116+ch3 cells
were harvested and a single cell suspension with .95% viability
(5x10
6 cells) diluted in equal volume of Matrigel (BD Biosciences)
were injected subcutaneously into the right flank of each mouse.
After the tumors were established, as determined by caliper
measurements (xenograft tumor volumes were approximately 50–
75 mm
3 after 10 days of cell injection), the mice were randomized
into the following six groups (n=6–4): (a) Vehicle control, (b)
TMZ, (c) NSC-124854, and (d) NSC-124854 + TMZ. The doses
for NSC-124854 and TMZ were 10 mg/kg body weight and
20 mg/kg body weight, respectively. Drugs were administered
intraperitoneally (i.p.) every day for 5 consecutive days. Tumor
volume was measured weekly in each group. All mice were
euthanized when the tumor volume in the control mice reached
approximately 1,000 mm
3 (day 42). The mice were housed and
maintained under sterile conditions in facilities accredited by the
American Association for the Accreditation of Laboratory Animal
Care and in accordance with current regulations and standards of
the United States Department of Agriculture, United States
Department of Health and Human Services, and the NIH.
Statistical analysis
The statistical significance between experimental groups and
control was determined by Student’s ‘t’ test. For mouse xenograft
study the statistical significance of differential findings between
experimental groups and control was determined by two-way
ANOVA as implemented by GraphPad StatMate (GraphPad
Software, La Jolla, CA). P,0.05 was considered statistically
significant.
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